TritonPoint Partners LLC Buys Shares of 6,746 Merck & Co., Inc. $MRK

TritonPoint Partners LLC bought a new stake in Merck & Co., Inc. (NYSE:MRK) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 6,746 shares of the company’s stock, valued at approximately $716,000.

Several other institutional investors also recently bought and sold shares of MRK. Norges Bank acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $3,997,933,000. DLD Asset Management LP boosted its stake in Merck & Co., Inc. by 30.1% in the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock valued at $3,986,675,000 after acquiring an additional 11,000,000 shares in the last quarter. Cardano Risk Management B.V. acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $1,012,530,000. Jennison Associates LLC acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $585,192,000. Finally, Marshall Wace LLP boosted its stake in Merck & Co., Inc. by 985.4% in the fourth quarter. Marshall Wace LLP now owns 3,969,469 shares of the company’s stock valued at $417,826,000 after acquiring an additional 3,603,769 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Trading Up 0.0%

NYSE:MRK opened at $119.05 on Monday. Merck & Co., Inc. has a 12 month low of $76.66 and a 12 month high of $125.14. The firm has a fifty day simple moving average of $116.55 and a 200-day simple moving average of $113.32. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The company has a market capitalization of $294.04 billion, a P/E ratio of 33.54, a PEG ratio of 2.68 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the previous year, the firm posted $2.22 earnings per share. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. The ex-dividend date is Monday, June 15th. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck Animal Health announced a definitive agreement to acquire TARGAN, a poultry biodevice company, which could strengthen Merck’s animal health division and broaden its technology-driven growth opportunities. Merck Animal Health to Acquire TARGAN
• Positive Sentiment: Merck saw unusually heavy call option buying, with traders purchasing 170,441 calls, a sharp jump versus normal volume that often signals bullish expectations from sophisticated investors.
• Positive Sentiment: Wells Fargo reiterated a buy rating on Merck, while another article highlighted that Wall Street’s overall bullish view continues to keep MRK on investors’ radar.
• Neutral Sentiment: Merck has also been featured in broader market commentary and “most searched” lists, suggesting rising attention rather than a new fundamental catalyst.
• Neutral Sentiment: One article noted Merck’s recent trading uptick but said it lagged the broader market, indicating modest price strength rather than a major breakout. Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Analysts Set New Price Targets

Several brokerages have weighed in on MRK. UBS Group raised their target price on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Barclays assumed coverage on shares of Merck & Co., Inc. in a research note on Friday, February 20th. They issued an “overweight” rating and a $140.00 target price for the company. Royal Bank Of Canada reiterated an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, March 30th. Zacks Research upgraded shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 17th. Finally, Wells Fargo & Company lowered their price objective on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $128.18.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.